DOCSLIB.ORG

WO 2017/223239 Al 28 December 2017 (28.12.2017) W !P O PCT

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2017/223239 Al 28 December 2017 (28.12.2017) W !P O PCT (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2017/223239 Al 28 December 2017 (28.12.2017) W !P O PCT (51) International Patent Classification: Published: A61K 31/445 (2006.01) C07D 471/04 (2006.01) — with international search report (Art. 21(3)) A61K 31/437 {2006.01) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US20 17/038609 amendments (Rule 48.2(h)) (22) International Filing Date: 2 1 June 2017 (21 .06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/352,820 2 1 June 2016 (21 .06.2016) 62/456,526 08 February 2017 (08.02.2017) (71) Applicant: X4 PHARMACEUTICALS, INC. [US/US]; 955 Massachusetts Avenue; 4th Floor, Cambridge, Massa chusetts 02139 (US). (72) Inventors: BOURQUE, Elyse Marie Josee; 3115 Racine Street, Unit 214, Bellingham, Washington 98226 (US). SK- ERLJ, Renato; 12 Crocker Circle, West Newton, Massa chusetts 02465 (US). (74) Agent: REID, Andrea L., C. et al; One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 021 10-2605 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). © (54) Title: CXCR4 INHIBITORS AND USES THEREOF o (57) Abstract: The present invention provides compounds, compositions thereof, and methods of using the same. CXCR4 INHIBITORS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit under 35 U.S.C . § 119(e) of U.S. Provisional Application nos. 62/352,820, filed June 21, 2016, and 62/456,526, filed February 8, 2017, the contents of all of which are incorporated herein in their entireties by reference. TECHNICAL FIELD OF THE INVENTION [0002] The present invention relates to compounds and methods useful for inhibition of C-X- C receptor type 4 (CXCR4). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders. BACKGROUND OF THE INVENTION [0003] C-X-C chemokine receptor type 4 (CXCR4), also known as fusin or cluster of differentiation 184 (CD 184), is a seven transmembrane G-protein coupled receptor (GPCR) belonging to Class I GPCR or rhodopsin-like GPCR family. Under normal physiological conditions, CXCR4 carries out multiple roles and is principally expressed in the hematopoietic and immune systems. CXCR4 was initially discovered as one of the co-receptors involved in human immunodeficiency virus (HIV) cell entry. Subsequent studies showed that it is expressed in many tissues, including brain, thymus, lymphatic tissues, spleen, stomach, and small intestine, and also specific cell types such as hematopoietic stem cells (HSC), mature lymphocytes, and fibroblasts. CXCL12, previously designated SDF- Ια, is the only known ligand for CXCR4. CXCR4 mediates migration of stem cells during embryonic development as well as in response to injury and inflammation. Multiple roles have been demonstrated for CXCR4 in human diseases such as cellular proliferative disorders, Alzheimer's disease, HIV, rheumatoid arthritis, pulmonary fibrosis, and others. For example, expression of CXCR4 and CXCL12 have been noted in several tumor types. CXCL12 is expressed by cancer-associated fibroblast (CAFs) and is often present at high levels in the tumor microenvironment (TME). In clinical studies of a wide range of tumor types, including breast, ovarian, renal, lung, and melanoma, expression of CXCR4/CXCL12 has been associated with a poor prognosis and with an increased risk of metastasis to lymph nodes, lung, liver, and brain, which are sites of CXCL12 expression. CXCR4 is frequently expressed on melanoma cells, particularly the CD133+ population that is considered to represent melanoma stem cells; in vitro experiments and murine models have demonstrated that CXCL12 is chemotactic for such cells. [0004] Furthermore, there is now evidence implicating the CXCL12/CXCR4 axis in contributing to the loss or lack of tumor responsiveness to angiogenesis inhibitors (also referred to as "angiogenic escape"). In animal cancer models, interference with CXCR4 function has been demonstrated to alter the TME and sensitize the tumor to immune attack by multiple mechanisms such as elimination of tumor re-vascularization and increasing the ratio of CD8+ T cells to Treg cells. These effects result in significantly decreased tumor burden and increased overall survival in xenograft, syngeneic, and transgenic cancer models. See Vanharanta et al. (2013) Nat Med 19: 50-56; Gale and McColl (1999) BioEssays 21: 17-28; Highfill et al. (2014) Sci Transl Med 6 : ra67; Facciabene et al. (201 1) Nature 475: 226-230. [0005] These data underscore the significant, unmet need for CXCR4 inhibitors to treat the many diseases and conditions mediated by aberrant or undesired expression of the receptor, for example in cellular proliferative disorders. SUMMARY OF THE INVENTION [0006] It has now been found that compounds of the present invention, and pharmaceutically acceptable compositions thereof, are effective as CXCR4 inhibitors. In one aspect, the present invention provides a compound of Formula I : or a pharmaceutically acceptable salt thereof, wherein each variable is as defined and described herein. [0007] Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful for treating a variety of diseases, disorders or conditions, associated with CXC receptor type 4 (CXCR4). Such diseases, disorders, or conditions include cellular proliferative disorders (e.g., cancer) such as those described herein. DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS 1. General Description of Certain Embodiments of the Invention: [0008] Compounds of the present invention, and pharmaceutical compositions thereof, are useful as inhibitors of CXCR4. Without wishing to be bound by any particular theory, it is believed that compounds of the present invention, and pharmaceutical compositions thereof, may inhibit the activity of CXCR4 and thus treat certain diseases, such as cancer. [0009] It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as CXCR4 inhibitors. In one aspect, the present invention provides a compound of Formula I : or a pharmaceutically acceptable salt thereof, wherein: Ring A is a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; 6 each R is independently -R, halogen, -CN, -OR, -N(R) 2, -N0 2, -N 3, -SR, or -I^-R ; each R is independently hydrogen or an optionally substituted group selected from Ci-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8- 10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; 2 each L and L is independently a covalent bond or a Ci- bivalent straight or branched hydrocarbon chain wherein 1, 2, or 3 methylene units of the chain are independently and optionally replaced with -0-, -C(O)-, -C(0)0-, -OC(O)-, -N(R)-, -C(0)N(R)-, -(R)NC(O)-, - OC(0)N(R)-, -(R)NC(0)0-, -N(R)C(0)N(R)-, -S-, -SO-, -S0 2-, -S0 2N(R)-, -(R)NS0 2-, - C(S)-, -C(S)0-, -OC(S)-, -C(S)N(R)-, -(R)NC(S)-, -(R)NC(S)N(R)-, or -Cy-; each -Cy- is independently a bivalent optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, optionally substituted phenylene, an optionally substituted 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-3
Load more

Recommended publications
  • How I Treat Myelofibrosis
    From www.bloodjournal.org by guest on October 7, 2014. For personal use only. Prepublished online September 16, 2014; doi:10.1182/blood-2014-07-575373 How I treat myelofibrosis Francisco Cervantes Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication. Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved. From www.bloodjournal.org by guest on October 7, 2014. For personal use only. Blood First Edition Paper, prepublished online September 16, 2014; DOI 10.1182/blood-2014-07-575373 How I treat myelofibrosis By Francisco Cervantes, MD, PhD, Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain Correspondence: Francisco Cervantes, MD, Hematology Department, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. Phone: +34 932275428.
    [Show full text]
  • Palladium-Catalyzed Arene Functionalization Via Single- Electron Reduction of Selectfluor
    Palladium-Catalyzed Arene Functionalization via Single- Electron Reduction of Selectfluor The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Mazzotti, Anthony Renato. 2016. Palladium-Catalyzed Arene Functionalization via Single-Electron Reduction of Selectfluor. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences. Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:33840680 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Palladium-Catalyzed Arene Functionalization via Single-Electron Reduction of Selectfluor A dissertation presented by Anthony Renato Mazzotti to The Department of Chemistry and Chemical Biology In partial fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Chemistry Harvard University Cambridge, Massachusetts July 2016 © Anthony Renato Mazzotti All Rights Reserved. Dissertation Advisor: Professor Tobias Ritter Anthony Renato Mazzotti Palladium-Catalyzed Arene Functionalization via Single-Electron Reduction of Selectfluor Abstract Palladium-catalysis is commonly used in the functionalization of aromatic rings, ranging from prefunctionalized substrates such as aryl metals or aryl (pseudo)halides to the direct functionalization of aromatic C–H bonds. Palladium-catalyzed
    [Show full text]
  • Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives
    cancers Review Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives Shirin Hafezi 1 and Mohamed Rahmani 1,2,* 1 Research Institute of Medical & Health Sciences, University of Sharjah, P.O. Box 27272 Sharjah, United Arab Emirates; [email protected] 2 Department of Basic Medical Sciences, College of Medicine, University of Sharjah, P.O. Box 27272 Sharjah, United Arab Emirates * Correspondence: [email protected]; Tel.: +971-6505-7759 Simple Summary: Apoptosis, a programmed form of cell death, represents the main mechanism by which cells die. Such phenomenon is highly regulated by the BCL-2 family of proteins, which includes both pro-apoptotic and pro-survival proteins. The decision whether cells live or die is tightly controlled by a balance between these two classes of proteins. Notably, the pro-survival Bcl-2 proteins are frequently overexpressed in cancer cells dysregulating this balance in favor of survival and also rendering cells more resistant to therapeutic interventions. In this review, we outlined the most important steps in the development of targeting the BCL-2 survival proteins, which laid the ground for the discovery and the development of the selective BCL-2 inhibitor venetoclax as a therapeutic drug in hematological malignancies. The limitations and future directions are also discussed. Abstract: The major form of cell death in normal as well as malignant cells is apoptosis, which is a programmed process highly regulated by the BCL-2 family of proteins. This includes the antiapoptotic proteins (BCL-2, BCL-XL, MCL-1, BCLW, and BFL-1) and the proapoptotic proteins, which can be divided into two groups: the effectors (BAX, BAK, and BOK) and the BH3-only proteins Citation: Hafezi, S.; Rahmani, M.
    [Show full text]
  • Discovery of Mcl-1 Inhibitors from Integrated High Throughput and Virtual Screening Received: 9 March 2018 Ahmed S
    www.nature.com/scientificreports OPEN Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening Received: 9 March 2018 Ahmed S. A. Mady1,3, Chenzhong Liao1,8, Naval Bajwa1,9, Karson J. Kump1,4, Accepted: 5 June 2018 Fardokht A. Abulwerdi 1,3,10, Katherine L. Lev1, Lei Miao 1, Sierrah M. Grigsby1,2, Published: xx xx xxxx Andrej Perdih5, Jeanne A. Stuckey6, Yuhong Du7, Haian Fu 7 & Zaneta Nikolovska-Coleska1,2,3,4 Protein-protein interactions (PPIs) represent important and promising therapeutic targets that are associated with the regulation of various molecular pathways, particularly in cancer. Although they were once considered “undruggable,” the recent advances in screening strategies, structure-based design, and elucidating the nature of hot spots on PPI interfaces, have led to the discovery and development of successful small-molecule inhibitors. In this report, we are describing an integrated high-throughput and computational screening approach to enable the discovery of small-molecule PPI inhibitors of the anti- apoptotic protein, Mcl-1. Applying this strategy, followed by biochemical, biophysical, and biological characterization, nineteen new chemical scafolds were discovered and validated as Mcl-1 inhibitors. A novel series of Mcl-1 inhibitors was designed and synthesized based on the identifed difuryl-triazine core scafold and structure-activity studies were undertaken to improve the binding afnity to Mcl- 1. Compounds with improved in vitro binding potency demonstrated on-target activity in cell-based studies. The obtained results demonstrate that structure-based analysis complements the experimental high-throughput screening in identifying novel PPI inhibitor scafolds and guides follow-up medicinal chemistry eforts.
    [Show full text]
  • Marine Natural Products: a Source of Novel Anticancer Drugs
    marine drugs Review Marine Natural Products: A Source of Novel Anticancer Drugs Shaden A. M. Khalifa 1,2, Nizar Elias 3, Mohamed A. Farag 4,5, Lei Chen 6, Aamer Saeed 7 , Mohamed-Elamir F. Hegazy 8,9, Moustafa S. Moustafa 10, Aida Abd El-Wahed 10, Saleh M. Al-Mousawi 10, Syed G. Musharraf 11, Fang-Rong Chang 12 , Arihiro Iwasaki 13 , Kiyotake Suenaga 13 , Muaaz Alajlani 14,15, Ulf Göransson 15 and Hesham R. El-Seedi 15,16,17,18,* 1 Clinical Research Centre, Karolinska University Hospital, Novum, 14157 Huddinge, Stockholm, Sweden 2 Department of Molecular Biosciences, the Wenner-Gren Institute, Stockholm University, SE 106 91 Stockholm, Sweden 3 Department of Laboratory Medicine, Faculty of Medicine, University of Kalamoon, P.O. Box 222 Dayr Atiyah, Syria 4 Pharmacognosy Department, College of Pharmacy, Cairo University, Kasr el Aini St., P.B. 11562 Cairo, Egypt 5 Department of Chemistry, School of Sciences & Engineering, The American University in Cairo, 11835 New Cairo, Egypt 6 College of Food Science, Fujian Agriculture and Forestry University, Fuzhou, Fujian 350002, China 7 Department of Chemitry, Quaid-i-Azam University, Islamabad 45320, Pakistan 8 Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Staudingerweg 5, 55128 Mainz, Germany 9 Chemistry of Medicinal Plants Department, National Research Centre, 33 El-Bohouth St., Dokki, 12622 Giza, Egypt 10 Department of Chemistry, Faculty of Science, University of Kuwait, 13060 Safat, Kuwait 11 H.E.J. Research Institute of Chemistry,
    [Show full text]
  • Anomalous Products in the Halogenation Reactions of Vinca Alkaloids 1.949
    Send Orders for Reprints to [email protected] 2639 Current Organic Chemistry, 2016, 20, 2639-2646 RESEARCH ARTICLE ISSN: 1385-2728 eISSN: 1875-5348 Impact Factor: Anomalous Products in the Halogenation Reactions of Vinca Alkaloids 1.949 BENTHAM SCIENCE András Keglevich,1 László Hegeds,2 Lilla Péter,1 Judit Gyenese,1 Csaba Szántay, Jr.,3 Zsófia Dubrovay,3+ Miklós Dékány,3 Áron Szigetvári,3 Ana Martins,4++ József Molnár,4 Attila Hunyadi,5 Péter Keglevich1* and László Hazai1* 1Department of Organic Chemistry and Technology, University of Technology and Economics, Budapest, Hungary, H-1111 Budapest, Gellért tér 4. Hungary; 2MTA–BME Organic Chemical Technology Research Group, Hungarian Academy of Sciences, Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, Budafoki út 8, H-1111 Budapest, Hungary; 3Spectroscopic Research Division, Gedeon Richter Plc., H-1475 Budapest 10, P. O. Box 27, Hungary; 4Department of Medical Microbiology and Immunobiology, University of Szeged, 6720 Szeged, Dóm tér 10., Hungary; 5Institute of Pharmacognosy, University of Szeged, H-6720 Szeged, Eötvös u. 6., Hungary Abstract: Halogenation reactions of vindoline and 14,15-dihydrovindoline and its hydro- chloric salt were investigated and the anomalous reductions were discussed. Performing the hydrogenation in the presence of chlorine-containing solvent, e.g. dichloromethane, hydrogenolysation reaction of chlorine also took place. In this case unexpected chlorin- ated product could be observed. Performing the hydrogenation reaction only in the pres- ence of methanol, the expected reduced derivative was obtained. Upon bromination of vindoline with excess NBS, oxidation products with ring contraction and developing an oxygen bridge were isolated. The fluorination reactions of vinblastine using Selectfluor® and xenon difluoride as the fluorination reagents were unsuccessful because of the de- composition of the starting material.
    [Show full text]
  • The Automated Flow Synthesis of Fluorine Containing Organic Compounds
    The automated flow synthesis of fluorine containing organic compounds by CHANTAL SCHOLTZ Submitted in partial fulfilment of the requirements for the degree PHILOSOPHAE DOCTOR In the Faculty of Natural & Agricultural Sciences UNIVERSITY OF PRETORIA PRETORIA Supervisor: Dr D.L. Riley February 2019 DECLARATION I, Chantal Scholtz declare that the thesis/dissertation, which I hereby submit for the degree PhD Chemistry at the University of Pretoria, is my own work and has not previously been submitted by me for a degree at this or any other tertiary institution. Signature :.......................................... Date :..................................... ii ACKNOWLEDGEMENTS I would herewith sincerely like to show my gratitude to the following individuals for their help, guidance and assistance throughout the duration of this project: My supervisor, Doctor Darren Riley, for his knowledge and commitment. Thank you for being a fantastic supervisor and allowing me the opportunity to learn so many valuable skills. My husband, Clinton, for all your love, support and patience and for always being there for me. You are the best. My family, for all the encouragement and support you gave me as well as always believing in me. I will always appreciate what you have done for me. Mr Drikus van der Westhuizen and Mr Johan Postma for their assistance at the Pelchem laboratories with product isolation and characterisation. Dr Mamoalosi Selepe for NMR spectroscopy services, Jeanette Strydom for XRF services and Gerda Ehlers at the UP library for her invaluable assistance. All my friends and colleagues for the continuous moral support, numerous helpful discussions and necessary coffee breaks. My colleagues at Chemical Process Technologies for their ongoing support and motivation, especially Dr Hannes Malan and Prof.
    [Show full text]
  • BCL-2 Inhibitors for Chronic Lymphocytic Leukemia
    L al of euk rn em u i o a J Robak, J Leuk 2015, 3:3 Journal of Leukemia DOI: 10.4172/2329-6917.1000e114 ISSN: 2329-6917 Editorial Open access BCL-2 inhibitors for Chronic Lymphocytic Leukemia Tadeusz Robak* Department of Hematology, Medical University of Lodz, 93-510 Lodz, ul, Ciolkowskiego 2, Poland *Corresponding author: Tadeusz Robak, Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93-510 Lodz, Ul. Ciolkowskiego 2, Poland, Tel: +48 42 6895191; E-mail: [email protected] Rec date: August 10, 2015; Acc date: August 12, 2015; Pub date: August 24, 2015 Copyright: © 2015 Robak T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Editorial cyclophosphamide and rituximab (FCR) or bendamustin-rituximab (BR) regimens in refractory CLL are ongoing (NCT00868413). B-cell chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Europe and North America, with an annual Venetoclax ( GDC-0199, ABT-199, RG7601; Genentech, South San incidence of three to five cases per 100,000 [1]. The approval of Francisco, CA), is a first-in-class, orally bioavailable BCL-2 family rituximab-based immunochemotherapy represented a substantial protein inhibitor that binds with high affinity to BCL-2 and with lower therapeutic advance in CLL [2]. However, currently available therapies affinity to the other BCL-2 family proteins Bcl-xL, Bcl-w and Mcl-1 are only partially efficient, and there is an obvious need to develop [14].
    [Show full text]
  • Phenotype-Based Drug Screening Reveals Association Between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia
    Acute Myeloid Leukemia SUPPLEMENTARY APPENDIX Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia Heikki Kuusanmäki, 1,2 Aino-Maija Leppä, 1 Petri Pölönen, 3 Mika Kontro, 2 Olli Dufva, 2 Debashish Deb, 1 Bhagwan Yadav, 2 Oscar Brück, 2 Ashwini Kumar, 1 Hele Everaus, 4 Bjørn T. Gjertsen, 5 Merja Heinäniemi, 3 Kimmo Porkka, 2 Satu Mustjoki 2,6 and Caroline A. Heckman 1 1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki; 2Hematology Research Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki; 3Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland; 4Department of Hematology and Oncology, University of Tartu, Tartu, Estonia; 5Centre for Cancer Biomarkers, De - partment of Clinical Science, University of Bergen, Bergen, Norway and 6Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.214882 Received: December 17, 2018. Accepted: July 8, 2019. Pre-published: July 11, 2019. Correspondence: CAROLINE A. HECKMAN - [email protected] HEIKKI KUUSANMÄKI - [email protected] Supplemental Material Phenotype-based drug screening reveals an association between venetoclax response and differentiation stage in acute myeloid leukemia Authors: Heikki Kuusanmäki1, 2, Aino-Maija
    [Show full text]
  • Identifying the Druggable Interactome of EWS-FLI1 Reveals MCL-1 Dependent Differential Sensitivities of Ewing Sarcoma Cells to Apoptosis Inducers
    www.oncotarget.com Oncotarget, 2018, Vol. 9, (No. 57), pp: 31018-31031 Research Paper Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers Kalliopi Tsafou1,7,*, Anna Maria Katschnig3,*, Branka Radic-Sarikas2,3,*, Cornelia Noëlle Mutz3, Kristiina Iljin5, Raphaela Schwentner3, Maximilian O. Kauer3, Karin Mühlbacher3, Dave N.T. Aryee3,4, David Westergaard1, Saija Haapa-Paananen5, Vidal Fey5, Giulio Superti-Furga2, Jeffrey Toretsky6, Søren Brunak1 and Heinrich Kovar3,4 1Disease Systems Biology, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark 2CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria 3Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria 4Department of Pediatrics, Medical University of Vienna, Vienna, Austria 5Medical Biotechnology, VTT Technical Research Centre of Finland, Espoo, Finland 6Department of Oncology, Georgetown University, Medical Center, Washington, DC, USA 7Current address: Broad Institute of MIT and Harvard, Cambridge, MA, USA *These authors contributed equally to this work Correspondence to: Heinrich Kovar, email: [email protected] Keywords: high-throughput compound screening; Ewing sarcoma; drug-target network; apoptosis; BCL-2 inhibitors Received: March 07, 2018 Accepted: June 22, 2018 Published: July 24, 2018 Copyright: Tsafou et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Ewing sarcoma (EwS) is an aggressive pediatric bone cancer in need of more effective therapies than currently available.
    [Show full text]
  • Durham E-Theses
    Durham E-Theses Selective Fluorination Strategies BREEN, JESSICA,RUTH How to cite: BREEN, JESSICA,RUTH (2012) Selective Fluorination Strategies, Durham theses, Durham University. Available at Durham E-Theses Online: http://etheses.dur.ac.uk/3479/ Use policy The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-prot purposes provided that: • a full bibliographic reference is made to the original source • a link is made to the metadata record in Durham E-Theses • the full-text is not changed in any way The full-text must not be sold in any format or medium without the formal permission of the copyright holders. Please consult the full Durham E-Theses policy for further details. Academic Support Oce, Durham University, University Oce, Old Elvet, Durham DH1 3HP e-mail: [email protected] Tel: +44 0191 334 6107 http://etheses.dur.ac.uk Abstract There is a great interest in the synthesis of fluorinated aromatic and heterocyclic compounds, which have a range of applications in the pharmaceutical industry. Many common routes to these compounds, however, are low yielding and or/expensive. This thesis is concerned with novel methods for the synthesis of fluoro-aromatics and fluoro- pyrazoles using conventional fluorinating agents, such as Selectfluor™, as well as using elemental fluorine and the flow reactor technology developed in Durham. Firstly, elemental fluorine was used to fluorinate a range of aromatics containing electron-donating substituents, using both batch and flow methods.
    [Show full text]
  • PLGA) Nanoparticles Across the Nasal Mucosa
    - In vitro assessment of the transport of Poly D, L Lactic-Co-Glycolic Acid (PLGA) nanoparticles across the nasal mucosa Albarki, Mohammed Abdulhussein Handooz https://iro.uiowa.edu/discovery/delivery/01IOWA_INST:ResearchRepository/12730608840002771?l#13730783320002771 Albarki, M. A. H. (2016). In vitro assessment of the transport of Poly D, L Lactic-Co-Glycolic Acid (PLGA) nanoparticles across the nasal mucosa [University of Iowa]. https://doi.org/10.17077/etd.cl2e1klm https://iro.uiowa.edu Copyright 2016 Mohammed Abdulhussein Handooz Albarki Downloaded on 2021/09/27 13:25:19 -0500 - IN VITRO ASSESSMENT OF THE TRANSPORT OF POLY D, L LACTIC-CO- GLYCOLIC ACID (PLGA) NANOPARTICLES ACROSS THE NASAL MUCOSA by Mohammed Abdulhussein Handooz Albarki A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in Pharmacy in the Graduate College of The University of Iowa August 2016 Thesis Supervisor: Professor Maureen D. Donovan Graduate College The University of Iowa Iowa City, Iowa CERTIFICATE OF APPROVAL ____________________________ MASTER'S THESIS _________________ This is to certify that the Master's thesis of Mohammed Abdulhussein Handooz Albarki has been approved by the Examining Committee for the thesis requirement for the Master of Science degree in Pharmacy at the August 2016 graduation. Thesis Committee: __________________________________________ Maureen D. Donovan, Thesis Supervisor __________________________________________ Aliasger K. Salem __________________________________________ Lewis L. Stevens To my parents for their continuous guidance throughout my life and career ii ACKNOWLEDGEMENTS I would like to express my deepest appreciation to my advisor, Professor Dr. Maureen Donovan. This thesis would not have been possible unless her thoughtful support and guidance.
    [Show full text]